Roivant reports $31M in LISRAYA net product revenue, successful Phase 3 uveitis trial results
Roivant reports strong commercial results from LISRAYA launch and positive top-line data from CLARITY-1 and CLARITY-2 NIU trials. Roivant has also announced initiatives to advance mosliciguat and planned investor meetings.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed